Journal
LEUKEMIA
Volume -, Issue -, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41375-023-02001-z
Keywords
-
Categories
Ask authors/readers for more resources
This is the primary report of the BRIGHT AML 1019 clinical trial, which investigated the use of glasdegib in combination with intensive or non-intensive chemotherapy for untreated acute myeloid leukemia patients. The study found that there was no significant improvement in overall survival when glasdegib was added to either chemotherapy regimen. The occurrence of treatment-emergent adverse events was similar between the glasdegib and placebo groups. Clinical trial registration: ClinicalTrials.gov: NCT03416179.
This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (n = 404; hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.782-1.408; two-sided p = 0.749) and non-intensive (n = 325; HR 0.99; 95% CI: 0.768-1.289; two-sided p = 0.969) studies. The proportion of patients who experienced treatment-emergent adverse events was similar for glasdegib versus placebo (intensive: 99.0% vs. 98.5%; non-intensive: 99.4% vs. 98.8%). The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study. The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Clinical trial registration: ClinicalTrials.gov: NCT03416179.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available